**Table S1 (supplementary material online).** Predictors of post-discharge all-cause death.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **HFpEF**  Adjusted HR (95% CI), *p* | **HFmrEF**  Adjusted HR (95% CI), *p* | **HFrEF**  Adjusted HR (95% CI), *p* | *p* for interaction |
| **Baseline characteristics** | | | | |
| Age ≥65 years | 2.6 (1.7-4.0), <0.001 | 1.4 (0.9-2.1), 0.102 | 1.6 (1.3-2.0), <0.001 | **0.07** |
| Female sex | 0.9 (0.7-1.1), 0.328 | 1.2 (0.8-1.7), 0.350 | 0.9 (0.8-1.2), 0.614 | 0.40 |
| Body mass index ≥25 kg/m2 | 0.8 (0.6-1.0), 0.064 | 0.9 (0.6-1.5), 0.798 | 0.9 (0.8-1.1), 0.498 | 0.50 |
| Ischemic etiology of heart failure | 0.8 (0.6-1.1), 0.216 | 1.2 (0.8-1.8), 0.297 | 1.0 (0.8-1.2), 0.892 | 0.24 |
| Previous heart failure hospitalization | 1.6 (1.2-2.1), 0.001 | 1.0 (0.7-1.4), 0.961 | 1.3 (1.1-1.5), 0.010 | 0.10 |
| Previous stroke/TIA | 1.3 (0.9-1.8), 0.191 | 1.5 (1.0-2.5), 0.073 | 1.0 (0.8-1.4), 0.815 | 0.33 |
| History of atrial fibrillation | 1.3 (0.9-1.8), 0.118 | 1.1 (0.8-1.7), 0.480 | 1.0 (0.8-1.2), 0.994 | 0.33 |
| Peripheral vascular disease | 0.9 (0.6-1.4), 0.680 | 1.0 (0.6-1.6), 0.864 | 1.2 (0.9-1.5), 0.175 | 0.47 |
| Diabetes | 1.0 (0.8-1.3), 0.992 | 1.0 (0.7-1.4), 0.966 | 1.2 (1.0-1.4), 0.100 | 0.54 |
| Chronic obstructive pulmonary disease | 1.1 (0.8-1.5), 0.558 | 1.3 (0.9-2.0), 0.184 | 0.9 (0.7-1.1), 0.447 | 0.26 |
| Hepatic dysfunction | 1.3 (0.9-2.0), 0.178 | 1.7 (0.9-3.2), 0.100 | 2.1 (1.6-2.7), <0.001 | 0.18 |
| Cancer disease | 1.6 (1.0-2.4), 0.037 | 2.2 (1.3-3.7), 0.003 | 0.7 (0.4-1.1), 0.157 | **0.004** |
| Depression | 0.6 (0.4-1.0), 0.067 | 0.5 (0.2-1.3), 0.174 | 1.0 (0.7-1.4), 0.986 | 0.21 |
| **Reason for index heart failure decompensation** | | | | |
| Atrial fibrillation | 1.0 (0.7-1.3), 0.754 | 1.0 (0.6-1.5), 0.868 | 0.9 (0.7-1.2), 0.404 | 1.00 |
| Myocardial ischemia | 0.6 (0.4-1.1), 0.114 | 0.9 (0.6-1.5), 0.821 | 1.0 (0.8-1.3), 0.843 | 0.26 |
| Infection | 1.4 (1.0-1.9), 0.027 | 1.3 (0.9-2.0), 0.196 | 1.3 (1.0-1.7), 0.030 | 0.88 |
| Worsening renal function | 1.5 (1.1-2.0), 0.015 | 1.5 (1.0-2.3), 0.039 | 1.2 (1.0-1.6), 0.061 | 0.55 |
| Uncontrolled hypertension | 1.0 (0.7-1.4), 0.995 | 1.0 (0.6-1.7), 0.924 | 0.9 (0.6-1.3), 0.499 | 0.81 |
| **In-hospital findings (echocardiography) and in-hospital treatment** | | | | |
| Mitral regurgitation (moderate to severe) | 1.4 (1.0-1.8), 0.025 | 1.4 (1.0-2.1), 0.082 | 1.2 (1.0-1.5), 0.094 | 0.57 |
| Tricuspid regurgigation (moderate to severe) | 1.3 (0.9-1.7), 0.145 | 1.1 (0.7-1.5), 0.747 | 1.2 (1.0-1.4), 0.125 | 0.75 |
| Inotropic support | 1.2 (0.7-2.1), 0.474 | 1.3 (0.7-2.3), 0.415 | 1.0 (0.8-1.2), 0.713 | 0.54 |
| PCI/CABG | 1.2 (0.6-2.5), 0.622 | 1.0 (0.4-2.6), 0.984 | 0.8 (0.5-1.2), 0.243 | 0.53 |
| **Clinical and laboratory findings at discharge** | | | | |
| Heart rate ≥70 b.p.m. (for sinus rhythm)/ ≥80 b.p.m. (for AF) | 1.1 (0.9-1.5), 0.371 | 1.3 (0.9-1.8), 0.191 | 1.2 (1.0-1.4), 0.096 | 0.88 |
| Systolic blood pressure <110 mmHg | 1.5 (1.1-2.1), 0.009 | 1.5 (1.0-2.2), 0.066 | 1.3 (1.0-1.5), 0.024 | 0.49 |
| NYHA class III-IV | 1.6 (1.2-2.1), 0.003 | 1.7 (1.2-2.4), 0.007 | 1.1 (0.9-1.4), 0.220 | **0.08** |
| Hyponatremia (sodium <135 mmol/L) | 1.3 (0.9-1.9), 0.227 | 1.4 (0.8-2.3), 0.195 | 1.4 (1.2-1.8), 0.001 | 0.82 |
| eGFR <60 mL/min/1.73m2 | 1.1 (0.8-1.6), 0.435 | 1.1 (0.7-1.6), 0.702 | 1.0 (0.8-1.3), 0.963 | 0.89 |
| Anemia (hemoglobin <12 g/dL in women/ <13 g/dL in men) | 1.8 (1.3-2.5), <0.001 | 1.5 (0.9-2.2), 0.092 | 1.6 (1.3-1.9), <0.001 | 0.74 |
| **Pharmacotherapy at hospital discharge** | | | | |
| Diuretics | 1.2 (0.8-1.8), 0.350 | 1.2 (0.6-2.1), 0.610 | 0.8 (0.5-1.1), 0.097 | 0.15 |
| Aldosterone antagonists | 0.9 (0.7-1.2), 0.445 | 1.0 (0.7-1.5), 0.904 | 1.0 (0.8-1.2), 0.728 | 0.84 |
| ACEi/ARB/ARNIs | 0.7 (0.5-1.0), 0.021 | 0.8 (0.5-1.1), 0.164 | 0.8 (0.7-1.0), 0.079 | 0.76 |
| Beta-blockers | 0.9 (0.7-1.1), 0.302 | 1.0 (0.7-1.5), 0.916 | 0.6 (0.5-0.8), <0.001 | **0.03** |

Red *p*-values indicate significant differences between EF categories, orange *p*-values indicate a trend.

ACEi – angiotensin-converting enzyme inhibitor; AF – atrial fibrillation; ARB - angiotensin receptor blocker; ARNI - angiotensin receptor-nephrilysin inhibitor; b.p.m. – beats per minute; CABG – coronary artery bypass grafting; CI – confidence interval; EF – ejection fraction; eGFR – estimated glomerular filtration rate; HF – heart failure; HFmrEF – HF with mildly reduced ejection fraction; HFpEF – HF with preserved ejection fraction; HFrEF – HF with reduced ejection fraction; HR – hazard ratio; NYHA – New York Heart Association; PCI – percutaneous coronary intervention; TIA – transient ischemic attack